MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

Why Is Inflammatory Disease-Focused MoonLake Immunotherapeutics Stock Trading Higher Today? ↗

March 11, 2024

Results with MoonLake Immunotherapeutics' Nanobody sonelokimab in Psoriatic Arthritis. Achieve over 60% ACR50, 40% ACR70, and 80% PASI90 by week 24. Unprecedented improvements compared to competitors.

Via Benzinga

MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day

March 10, 2024

MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024

March 04, 2024

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

Expert Ratings for MoonLake ↗

November 27, 2023

Via Benzinga

Recap: MoonLake Q3 Earnings ↗

November 14, 2023

Via Benzinga

16 Analysts Have This to Say About MoonLake ↗

November 07, 2023

Via Benzinga

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)

February 26, 2024

The company tested its drug over 12 weeks in 207 patients. All but one regimen led to statistically significant improvements.

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

December 20, 2023

Via Benzinga

Where MoonLake Stands With Analysts ↗

October 16, 2023

Via Benzinga

The Latest Analyst Ratings for MoonLake ↗

September 18, 2023

Via Benzinga

Why Former Highflier MoonLake Plummeted 29% After A Recent Run ↗

November 06, 2023

U.S. stocks turned lower toward the end of trading, with the Dow Jones falling around 50 points on Monday The Dow traded down 0.16% to 34,007.81 while the NASDAQ fell 0.08% to 13,467.42. The S&P 500...

Dow Turns Lower; EchoStar Shares Plunge ↗

November 06, 2023

Via Benzinga

Topics Stocks

Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

November 06, 2023

Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge...

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 06, 2023

Via Benzinga

Crude Oil Moves Higher; BioNTech Lowers 2023 Sales Outlook ↗

November 06, 2023

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 40 points on Monday The Dow traded up 0.13% to 34,106.99 while the NASDAQ rose 0.16% to 13,499.42. The S&P 500 also...

Via Benzinga

Topics Stocks

Why Is Arthritis-Focused MoonLake Immunotherapeutics Stock Trading Lower Today? ↗

November 06, 2023

Sunday, MoonLake Immunotherapeutics (NASDAQ: MLTX) released topline results from its global Phase 2 ARGO trial of Nanobody sonelokimab in patients with

Via Benzinga

TreeHouse Foods, EchoStar, Hilton Grand Vacations, EchoStar And Other Big Stocks Moving Lower On Monday ↗

November 06, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 25 points on Monday. Here are some big stocks recording losses in today’s session.

Via Benzinga

Topics Stocks

US Stocks Rise; Nasdaq Gains 50 Points ↗

November 06, 2023

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 50 points on Monday Following the market opening Monday, the Dow traded up 0.21% to 34,133.62 while the NASDAQ rose...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

November 06, 2023

Via Benzinga

MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis

November 05, 2023

MoonLake Immunotherapeutics' Lead Skin Disorder Candidate Continues to Deliver on Best-Efficacy Profile: Analyst ↗

October 16, 2023

MoonLake Immunotherapeutics (NASDAQ: MLTX) announced 24-week topline results from its Phase 2 MIRA trial of sonelokimab for moderate-to-severe hidradenitis suppurativa (HS), following the 12-week...

Via Benzinga

Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

October 16, 2023

Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday.

Via Benzinga

Lululemon, PCTEL, Consolidated Communications, Other Stocks Jumping Higher On Monday ↗

October 16, 2023

U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Monday. Here are some stocks recording big gains in today’s session.

Via Benzinga

Topics Stocks

Why Top 1% Biotech MoonLake Just Surged Within Striking Distance Of A Breakout ↗

October 16, 2023

MoonLake says it's skin-disease treatment showed improved promise in a 24-week testing update.

MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa

October 15, 2023

MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress

October 11, 2023

Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.

7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio ↗

September 27, 2023

Via InvestorPlace

These 8 Stocks Are Outperforming Nvidia In 2023 ↗

September 18, 2023

Carvana has surged 1,001%, leading huge winners this year.